184 related articles for article (PubMed ID: 33382017)
1. Ensemble-based high-throughput virtual screening of natural ligands using the Super Natural-II database against cell-wall protein dTDP-4-dehydrorhamnose reductase (RmlD) in
Ravichandran R; Ridzwan NFW; Mohamad SB
J Biomol Struct Dyn; 2022 Jul; 40(11):5069-5078. PubMed ID: 33382017
[TBL] [Abstract][Full Text] [Related]
2. Structure prediction, molecular simulations of RmlD from Mycobacterium tuberculosis, and interaction studies of Rhodanine derivatives for anti-tuberculosis activity.
N H; P SR; Sura M; Daddam JR
J Mol Model; 2021 Feb; 27(3):75. PubMed ID: 33547544
[TBL] [Abstract][Full Text] [Related]
3. Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) identified by virtual screening.
Wang Y; Hess TN; Jones V; Zhou JZ; McNeil MR; Andrew McCammon J
Bioorg Med Chem Lett; 2011 Dec; 21(23):7064-7. PubMed ID: 22014548
[TBL] [Abstract][Full Text] [Related]
4. Virtual screening to identify novel potential inhibitors for Glutamine synthetase of
Kumari M; Subbarao N
J Biomol Struct Dyn; 2020 Oct; 38(17):5062-5080. PubMed ID: 31755360
[TBL] [Abstract][Full Text] [Related]
5. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae.
Kaur G; Pandey B; Kumar A; Garewal N; Grover A; Kaur J
J Biomol Struct Dyn; 2019 Mar; 37(5):1254-1269. PubMed ID: 29557724
[TBL] [Abstract][Full Text] [Related]
6. Structure based virtual screening and discovery of novel inhibitors against FabD protein of
Sundararajan S; Karunakaran K; Muniyan R
J Biomol Struct Dyn; 2024 Aug; 42(12):6280-6291. PubMed ID: 37424186
[TBL] [Abstract][Full Text] [Related]
7. Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose.
Ma Y; Stern RJ; Scherman MS; Vissa VD; Yan W; Jones VC; Zhang F; Franzblau SG; Lewis WH; McNeil MR
Antimicrob Agents Chemother; 2001 May; 45(5):1407-16. PubMed ID: 11302803
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel multitarget antitubercular inhibitors against mycobacterial peptidoglycan biosynthetic Mur enzymes by structure-based virtual screening.
Kumari M; Subbarao N
J Biomol Struct Dyn; 2022 Nov; 40(18):8185-8196. PubMed ID: 33826470
[TBL] [Abstract][Full Text] [Related]
9. Identification of peptidomimetic compounds as potential inhibitors against MurA enzyme of
Kumar P; Saumya KU; Giri R
J Biomol Struct Dyn; 2020 Oct; 38(17):4997-5013. PubMed ID: 31755364
[TBL] [Abstract][Full Text] [Related]
10. GacA is essential for Group A Streptococcus and defines a new class of monomeric dTDP-4-dehydrorhamnose reductases (RmlD).
van der Beek SL; Le Breton Y; Ferenbach AT; Chapman RN; van Aalten DM; Navratilova I; Boons GJ; McIver KS; van Sorge NM; Dorfmueller HC
Mol Microbiol; 2015 Dec; 98(5):946-62. PubMed ID: 26278404
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
Saxena S; Abdullah M; Sriram D; Guruprasad L
J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential non-nucleoside MraY inhibitors for tuberculosis chemotherapy using structure-based virtual screening.
Pandey P; Chatterjee S; Berida T; Doerksen RJ; Roy S
J Biomol Struct Dyn; 2022 Jul; 40(11):4832-4849. PubMed ID: 33353500
[TBL] [Abstract][Full Text] [Related]
13. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of
Mahfuz AMUB; Stambuk Opazo F; Aguilar LF; Iqbal MN
J Biomol Struct Dyn; 2022 Jun; 40(9):4021-4037. PubMed ID: 33251968
[TBL] [Abstract][Full Text] [Related]
15. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
[TBL] [Abstract][Full Text] [Related]
16. In silico Screening of Food and Drug Administration-approved Compounds against Trehalose 2-sulfotransferase (Rv0295c) in Mycobacterium tuberculosis: Insights from Molecular Docking and Dynamics Simulations.
Sharma D; Gautam S; Srivastava N; Bisht D
Int J Mycobacteriol; 2024 Jan; 13(1):73-82. PubMed ID: 38771283
[TBL] [Abstract][Full Text] [Related]
17. Structural insight into Mycobacterium tuberculosis maltosyl transferase inhibitors: pharmacophore-based virtual screening, docking, and molecular dynamics simulations.
Sengupta S; Roy D; Bandyopadhyay S
J Biomol Struct Dyn; 2015; 33(12):2655-66. PubMed ID: 25669125
[TBL] [Abstract][Full Text] [Related]
18. Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors.
Kumar R; Garg P; Bharatam PV
J Biomol Struct Dyn; 2015; 33(5):1082-93. PubMed ID: 24875451
[TBL] [Abstract][Full Text] [Related]
19. Characterization of dTDP-4-dehydrorhamnose 3,5-epimerase and dTDP-4-dehydrorhamnose reductase, required for dTDP-L-rhamnose biosynthesis in Salmonella enterica serovar Typhimurium LT2.
Graninger M; Nidetzky B; Heinrichs DE; Whitfield C; Messner P
J Biol Chem; 1999 Aug; 274(35):25069-77. PubMed ID: 10455186
[TBL] [Abstract][Full Text] [Related]
20. Probing the structure of Mycobacterium tuberculosis MbtA: model validation using molecular dynamics simulations and docking studies.
Maganti L; Open Source Drug Discovery Consortium ; Ghoshal N
J Biomol Struct Dyn; 2014; 32(2):273-88. PubMed ID: 23527569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
